USD/SGD remains under pressure after forming a bearish flag and double-top, with weak US economic data and strong Singapore growth pointing to a potential drop toward 1.2900.
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?